S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NYSE:EW

Edwards Lifesciences (EW) Stock Price, News & Analysis

$95.15
+1.73 (+1.85%)
(As of 03/27/2024 ET)
Today's Range
$93.59
$95.35
50-Day Range
$72.55
$94.68
52-Week Range
$60.57
$95.35
Volume
3.65 million shs
Average Volume
4.08 million shs
Market Capitalization
$57.21 billion
P/E Ratio
41.37
Dividend Yield
N/A
Price Target
$88.50

Edwards Lifesciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
6.7% Downside
$88.80 Price Target
Short Interest
Healthy
1.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.57mentions of Edwards Lifesciences in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$16.45 M Sold Last Quarter
Proj. Earnings Growth
12.32%
From $2.76 to $3.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

136th out of 939 stocks

Surgical Appliances & Supplies Industry

5th out of 16 stocks

EW stock logo

About Edwards Lifesciences Stock (NYSE:EW)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

EW Stock Price History

EW Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
EW Apr 2024 100.000 call
CAH Apr 2024 123.000 call
EW Aug 2024 97.500 call
TMO Mar 2024 572.500 call
EW Jun 2024 65.000 call
Edwards Lifesciences Corp.
Validea Detailed Fundamental Analysis - EW
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Today
3/28/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
CUSIP
28176E10
Employees
19,800
Year Founded
1958

Price Target and Rating

Average Stock Price Target
$88.50
High Stock Price Target
$107.00
Low Stock Price Target
$57.00
Potential Upside/Downside
-7.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
18 Analysts

Profitability

Net Income
$1.40 billion
Pretax Margin
26.61%

Debt

Sales & Book Value

Annual Sales
$6.00 billion
Cash Flow
$2.82 per share
Book Value
$11.08 per share

Miscellaneous

Free Float
593,543,000
Market Cap
$57.21 billion
Optionable
Optionable
Beta
1.05

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Edwards Lifesciences was last updated on Tuesday, March 26, 2024 at 11:11 PM.

Pros

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

  • Edwards Lifesciences Co. has a strong market capitalization of $55.51 billion, indicating stability and potential for growth.
  • The company offers innovative transcatheter heart valve replacement products under the Edwards SAPIEN family, which are in high demand due to their minimally invasive nature and effectiveness.
  • Recent institutional investments in Edwards Lifesciences, such as Nordea Investment Management AB's significant stake increase, reflect confidence in the company's future performance.
  • Edwards Lifesciences Co. has a diverse product portfolio, including critical care monitoring systems like FloTrac and HemoSphere, catering to a wide range of healthcare needs.
  • The stock price of Edwards Lifesciences Co. has shown resilience, with a 52-week high of $95.27, indicating positive investor sentiment and potential for returns.

Cons

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

  • Edwards Lifesciences Co. operates in the highly competitive healthcare equipment industry, facing challenges from other established players and potential market saturation.
  • The company's price-to-earnings ratio of 40.13 and price-to-earnings-growth ratio of 4.61 may indicate a relatively high valuation, potentially limiting short-term gains for investors.
  • While recent institutional investments show confidence, they also raise concerns about potential market fluctuations impacting the stock price of Edwards Lifesciences Co.
  • Investors should consider the company's debt-to-equity ratio of 0.09, as higher debt levels can pose risks during economic downturns or challenging market conditions.
  • Market volatility and regulatory changes in the healthcare sector could impact the performance of Edwards Lifesciences Co., leading to uncertainties for investors.

EW Stock Analysis - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EW shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price target for 2024?

17 analysts have issued 12-month price targets for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they expect the company's share price to reach $88.80 in the next twelve months. This suggests that the stock has a possible downside of 6.7%.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2024?

Edwards Lifesciences' stock was trading at $76.25 at the beginning of 2024. Since then, EW shares have increased by 24.8% and is now trading at $95.15.
View the best growth stocks for 2024 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 10,450,000 shares, an increase of 23.8% from the February 29th total of 8,440,000 shares. Based on an average trading volume of 3,940,000 shares, the short-interest ratio is currently 2.7 days. Approximately 1.8% of the company's stock are sold short.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings data on Tuesday, February, 6th. The medical research company reported $0.64 EPS for the quarter, hitting analysts' consensus estimates of $0.64. The medical research company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 23.56% and a net margin of 23.35%. Edwards Lifesciences's quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.64 EPS.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Shares of Edwards Lifesciences split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were payable to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of 0.620-0.660 for the period, compared to the consensus EPS estimate of 0.660. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.71%), Vanguard Group Inc. (8.63%), Brown Advisory Inc. (3.00%), Wellington Management Group LLP (2.80%), Capital International Investors (1.49%) and Norges Bank (1.40%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
This page (NYSE:EW) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners